All treatments
Treatment
KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-7684A clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
This study looks at a new combination treatment (Vibostolimab with Pembrolizumab) for melanoma skin cancer that has a high chance of coming back. It compares this combination to an existing treatment (Pembrolizumab alone) to see if it can stop the cancer from returning.
For: melanomaAustria · France · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer (KEYVIBE-003)
This study is looking at a new combination medicine, MK-7684A, compared to an existing treatment, Keytruda, for advanced lung cancer. It aims to see if the new combination can help people live longer when their cancer has a specific marker called PD-L1.
For: Stage IV non small-cell lung cancerRomania · Hungary